Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Gilead is a global biopharmaceutical company focused on virology (HIV, Hepatitis), oncology, and inflammation. The company operates in over 35 countries with headquarters in Foster City, California. Key commercial products include Biktarvy (HIV), Epclusa (Hepatitis C), Livdelzi (PBC), and Trodelvy (Oncology).
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $29,443 | $28,754 | +2% |
| Net Income Attributable to Gilead | $8,510 | $480 | NM |
| Diluted EPS | $6.78 | $0.38 | NM |
| Operating Income | $10,022 | $1,662 | NM |
| Product Gross Margin | 78.4% | 78.2% | +20 bps |
| Operating Cash Flow | $10,019 | $10,828 | -7% |
| Cash and Cash Equivalents (Year End) | $7,564 | $9,991 | -24% |
| Total Debt (Net) | $24,937 | $26,710 | -7% |
Note: "NM" indicates Not Meaningful due to the significant year-over-year variance in net income.
Material Changes vs. Prior Period
- Profitability Surge: Net income increased from $480 million in 2024 to $8.5 billion in 2025. This dramatic improvement was primarily driven by the absence of a $3.8 billion non-recurring acquired in-process research and development (IPR&D) expense related to the CymaBay acquisition in 2024 and significantly lower IPR&D impairment charges ($590 million in 2025 vs. $4.2 billion in 2024).
- Revenue Growth: Total revenues grew 2% to $29.4 billion. HIV product sales increased 6% to $20.8 billion, driven by Biktarvy (+7%) and Descovy (+31%). Liver Disease sales rose 6% to $3.2 billion, aided by Livdelzi. These gains were partially offset by a 49% decline in Veklury sales ($911 million) due to lower COVID-19 hospitalizations.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 5% to $5.8 billion. Research and development (R&D) expenses decreased 2% to $5.8 billion.
- Debt Reduction: The company repaid $1.75 billion of senior unsecured notes due in February 2025 and utilized $1.8 billion for debt repayment during the year.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- 2026 Expectations: Management expects continued growth in overall product sales, bolstered by HIV demand. This is anticipated to be partially offset by policy-related developments in the U.S., decreased Veklury sales, and competitive headwinds in Cell Therapy.
- Strategic Priorities: Focus on maximizing long-acting HIV therapies, accelerating the oncology and inflammation pipeline, and scaling artificial intelligence (AI) adoption.
- Capital Allocation: Continued focus on disciplined operating expense management, dividends, and share repurchases. A $6.0 billion stock repurchase program was authorized in Q3 2025.
Risks and Contingencies
- Regulatory and Pricing: Significant exposure to U.S. policy changes, including the Inflation Reduction Act (IRA) and the "One Big Beautiful Bill" (OBBB) Act. Biktarvy was selected for Medicare price negotiation effective 2028. The company reached an agreement with the U.S. administration to pause Section 232 tariffs for three years and implement Most Favored Nation (MFN) pricing in Medicaid for select products.
- Patent Litigation: Settled Biktarvy patent litigation with Lupin, Cipla, and Laurus Labs, delaying generic entry in the U.S. to April 1, 2036. New litigation filed against Cipla regarding Descovy in February 2026.
- Clinical Trial Risks: The Phase 3 ASCENT-07 study for Trodelvy in HR+/HER2- metastatic breast cancer did not meet its primary endpoint. The Phase 3 STAR-221 study for domvanalimab/zimberelimab was discontinued.
- Legal Proceedings: Ongoing antitrust and consumer protection litigation regarding HIV drugs; product liability lawsuits regarding kidney and bone injuries; and qui tam litigation regarding HCV sales practices.
Investor Verification Checklist
- Recurring vs. Non-Recurring Income: Verify the sustainability of the 2025 net income surge by analyzing the specific non-recurring charges in 2024 (CymaBay IPR&D and Trodelvy NSCLC impairments) to ensure they do not mask underlying operational trends.
- Medicare Negotiation Impact: Assess the potential financial impact of the 2028 Medicare price negotiation for Biktarvy, the company's top-selling product.
- Patent Expiration Timeline: Confirm the validity of the April 2036 generic entry date for Biktarvy following the recent settlement agreements.
- Policy Risk Exposure: Evaluate the financial implications of the MFN pricing agreement with the U.S. government and the expiration of ACA premium subsidies under the OBBB Act.
- Pipeline Viability: Review the status of key oncology candidates (Trodelvy, Anitocabtagene autoleucel) following recent clinical trial setbacks and the pending acquisition of Arcellx.